Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
SOLENO THERAPEUTICS INC (SLNO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Soleno Therapeutics, Inc. Condensed Consolidated Balance Sheets"
05/09/2023 8-K Quarterly results
Docs: "REDWOOD CITY, Calif., May 9, 2023 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 and Recent Corporate Highlights"
03/21/2023 8-K Quarterly results
Docs: "REDWOOD CITY, Calif., March 21, 2023 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 and Recent Corporate Highlights"
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results REDWOOD CITY, Calif., November 10, 2021 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine months ended September 30, 2021. “The recently announced top-line results from Soleno's ongoing open-label extension study evaluating DCCR for the treatment of Prader-Willi syndrome , and the comparison of these data to matched subjects from the PATH for PWS natural history study, highlight the compelling potential of this promising therapy in addressing the myriad physical and behavioral challenges faced by PWS patients and families..."
07/28/2021 8-K Quarterly results
Docs: "Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results REDWOOD CITY, Calif., July 28, 2021 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021. “The Soleno team remains focused on achieving regulatory approval for DCCR for the treatment of Prader-Willi syndrome, or PWS,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We are continuing our dialogue with the U.S. Food and Drug Administration and, as recently announced, intend to submit the clinical study reports from DESTINY PWS and the C602 extension study, as well as addi..."
05/05/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results REDWOOD CITY, Calif., November 10, 2020 - Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter and nine months ended September 30, 2020. Third Quarter 2020 and Recent Corporate Highlights"
08/10/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
03/04/2020 8-K Quarterly results
11/13/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 7, 2019 SOLENO THERAPEUTICS, INC. Delaware 001-36593 77-0523891 1235 Radio Road, Suite 110 Redwood City, CA 94065 213-8444 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Ex...",
"Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results"
05/13/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 13, 2019 SOLENO THERAPEUTICS, INC. Delaware 001-36593 77-0523891 1235 Radio Road, Suite 110 Redwood City, CA 94065 213-8444 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exc...",
"Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results"
03/18/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 18, 2019 SOLENO THERAPEUTICS, INC. Delaware 001-36593 77-0523891 1235 Radio Road, Suite 110 Redwood City, CA 94065 213-8444 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Ex...",
"Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results"
11/15/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results"
08/14/2018 8-K Quarterly results
Docs: "Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results"
05/16/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results"
05/04/2015 8-K Form 8-K - Current report
12/18/2014 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy